Overview

Useful For
Monitoring treatment of patients with porphyria cutanea tarda

Genetics Test Information
Plasma specimens from patients with active porphyria cutanea tarda, congenital erythropoietic porphyria, and erythropoietic protoporphyria may exhibit increased plasma porphyrin levels. However, a definitive diagnosis cannot be made by plasma analysis alone.

Highlights
Plasma porphyrins are most appropriate for monitoring patients being treated for porphyria cutanea tarda.

Analysis of plasma porphyrins is suitable for individuals with bullous dermatosis who are in chronic renal failure and unable to provide a urine specimen.

Reflex Tests

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Reporting Name</th>
<th>Available Separately</th>
<th>Always Performed</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFP</td>
<td>Porphyrins, Fractionation, P</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

Testing Algorithm
If total porphyrins are above 1.0 mcg/dL, then porphyrin fractionation will be performed at an additional charge.

The following algorithms are available in Special Instructions:

- Porphyria (Acute) Testing Algorithm
- Porphyria (Cutaneous) Testing Algorithm

Special Instructions
- The Heme Biosynthetic Pathway
- Porphyria (Acute) Testing Algorithm
- Porphyria (Cutaneous) Testing Algorithm

Method Name
PTP: Extraction and Scanning Spectrofluorometry

PFP: High-Performance Liquid Chromatography (HPLC)

NY State Available
Yes

Specimen

Specimen Type
Plasma
Shipping Instructions

Ship specimen in amber vial to protect from light.

Necessary Information

Include a list of medications the patient is currently taking.

Specimen Required

**Patient Preparation:** Patient should abstain from alcohol for at least 24 hours prior to specimen collection.

**Supplies:** Amber Frosted Tube, 5 mL (T192)

**Collection Container/Tube:**

- **Preferred:** Green top (heparin)
- **Acceptable:** Lavender top (EDTA)

**Submission Container/Tube:** Amber vial

**Specimen Volume:** 3 mL

**Collection Instructions:**

1. Centrifuge specimen and aliquot plasma into amber vial.
2. Send plasma frozen.

**Forms**

If not ordering electronically, complete, print, and send an Inborn Errors of Metabolism Test Request (T798) with the specimen.

**Specimen Minimum Volume**

1 mL

**Reject Due To**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross hemolysis</td>
<td>OK</td>
</tr>
<tr>
<td>Gross lipemia</td>
<td>OK</td>
</tr>
<tr>
<td>Gross icterus</td>
<td>OK</td>
</tr>
</tbody>
</table>

**Specimen Stability Information**

<table>
<thead>
<tr>
<th>Specimen Type</th>
<th>Temperature</th>
<th>Time</th>
<th>Special Container</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma</td>
<td>Frozen</td>
<td>14 days</td>
<td>LIGHT PROTECTED</td>
</tr>
</tbody>
</table>

**Clinical and Interpretive**
**Clinical Information**

The porphyrias are a group of inherited disorders resulting from enzyme defects in the heme biosynthetic pathway. These enzyme defects cause various porphyrins and their precursors to accumulate in different specimen types. The detection and differentiation of the porphyrias is through evaluation of the patterns of porphyrin accumulation observed in erythrocytes and plasma and of the heme precursors excreted in urine and feces.

The porphyrias are typically classified as erythropoietic or hepatic based upon the primary site of the enzyme defect. In addition, hepatic porphyrias can be further classified as chronic or acute, based on their clinical presentation.

The primary acute hepatic porphyrias, acute intermittent porphyria (AIP), hereditary coproporphyria (HCP), and variegate porphyria (VP), are associated with neurovisceral symptoms that typically onset during puberty or later. Common symptoms include severe abdominal pain, peripheral neuropathy, and psychiatric symptoms. A broad range of medications (including barbiturates and sulfa drugs), alcohol, infection, starvation, heavy metals, and hormonal changes may precipitate crises. Photosensitivity is not associated with AIP, but may occur in HCP and VP.

Cutaneous photosensitivity is associated with the chronic hepatic porphyria, porphyria cutanea tarda (PCT), and the erythropoietic porphyrias including erythropoietic protoporphyria (EPP), X-linked dominant protoporphyria (XLDPP), and congenital erythropoietic porphyria (CEP). Although genetic in nature, environmental factors may exacerbate symptoms, significantly impacting the severity and course of disease.

CEP is an erythropoietic porphyria caused by uroporphyrinogen III synthase deficiency. Symptoms typically present in early infancy with red-brown staining of diapers, severe cutaneous photosensitivity with fluid-filled bullae and vesicles. Other common symptoms may include thickening of the skin, hypo- and hyperpigmentation, hypertrichosis, cutaneous scarring, and deformities of the fingers, eyelids, lips, nose, and ears. A few milder adult-onset cases have been documented as well as cases that are secondary to myeloid malignancies.

PCT is the most common form of porphyria and can be either sporadic (acquired) or inherited in an autosomal dominant manner. The most prominent clinical characteristics are cutaneous photosensitivity and scarring on sun-exposed surfaces. Patients experience chronic blistering lesions; fluid-filled vesicles that rupture easily become crusted and heal slowly, which result from mild trauma to sun-exposed areas. Secondary infections can cause areas of hypo- or hyperpigmentation or sclerodermatous changes and alopecia following repeated skin damage. Liver disease is common as evidenced by abnormal liver function tests, and 30% to 40% of patients with PCT develop cirrhosis. In addition, there is an increased risk of hepatocellular carcinoma.

Hepatoerythropoietic porphyria (HEP) occurs when an individual inherits a PCT-causing genetic variant from both parents. Patients exhibit a similar clinical presentation to what is seen in CEP.

Clinical presentation of EPP and XLDPP is identical with onset of symptoms typically occurring in childhood. Cutaneous photosensitivity in sun-exposed areas of the skin generally worsens in the spring and summer months. Common symptoms may include itching, edema, erythema, stinging or burning sensations, and occasionally scarring of the skin in sun-exposed areas.

Plasma porphyrins are most appropriate for monitoring treatment of PCT. Although analysis in plasma is not recommended for diagnosis, increases in plasma porphyrin concentrations are observed in the cutaneous porphyrias and may be elevated during acute episodes of AIP, VP, and HCP. In addition, persons in chronic renal failure who develop bullous dermatosis similar to that associated with PCT may have increased plasma porphyrins.

The workup of patients with a suspected porphyria is most effective when following a stepwise approach.

The following algorithms are available in Special Instructions or call 800-533-1710 to discuss testing strategies:
Test Definition: PTP
Porphyrians, Total, P

Reference Values
< or =1.0 mcg/dL

Interpretation
Abnormal results are reported with a detailed interpretation that may include an overview of the results and their significance, a correlation to available clinical information provided with the specimen, differential diagnosis, recommendations for additional testing when indicated and available, and a phone number to reach one of the laboratory directors in case the referring physician has additional questions.

Cautions
Plasma porphyrins, especially protoporphyrin, are extremely sensitive to light and may degrade to normal levels if not handled properly.

Clinical Reference


Performance

Method Description
The plasma porphyrins profile is performed as a 2-step analysis. First, the total plasma porphyrins concentration is determined by extracting the porphyrins from plasma with a mixture of ethyl acetate and acetic acid. The porphyrins are then back extracted into dilute hydrochloric acid. Total porphyrins are quantified on this extract via scanning spectrophotometry. If the total plasma porphyrin concentration is elevated, the extract is submitted for HPLC analysis, whereby the individual porphyrin analytes are separated by differential partitioning between a stationary aliphatic surface and a moving aqueous buffer solution. As the porphyrins emerge separately from the column, the quantity of each is monitored with a fluorescence detector. (Ford RE, Ou C, Ellefson RD: Liquid chromatographic analysis for urinary porphyrins. Clin Chem 1981;27:397-401)

PDF Report
No

Day(s) and Time(s) Test Performed
Monday; 8 a.m.

Analytic Time
2 days (not reported Saturday or Sunday)

Maximum Laboratory Time
5 days
**Test Definition: PTP**

**Porphyrins, Total, P**

---

### Specimen Retention Time

14 days

### Performing Laboratory Location

Rochester

### Fees and Codes

#### Fees
- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact [Customer Service](#).

### Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

### CPT Code Information

- **84311-Porphyrins, total**
- **82542-Porphyrins, fractionation (if appropriate)**

### LOINC® Information

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Test Order Name</th>
<th>Order LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTP</td>
<td>Porphyrins, Total, P</td>
<td>2815-9</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Result ID</th>
<th>Test Result Name</th>
<th>Result LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>8731</td>
<td>Porphyrins, Total, P</td>
<td>2815-9</td>
</tr>
<tr>
<td>34252</td>
<td>Reviewed By</td>
<td>18771-6</td>
</tr>
<tr>
<td>33869</td>
<td>Interpretation</td>
<td>59462-2</td>
</tr>
</tbody>
</table>